{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:06:03Z","timestamp":1791223563181,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guselkumab, a monoclonal antibody targeting IL-23p19, has shown durable efficacy and safety in global phase III trials and real-world studies. However, in Chinese populations, comprehensive real-world evidence regarding its effects across disease severities, body areas, and metabolic parameters remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct a multidimensional evaluation of guselkumab in moderate to severe plaque psoriasis based on Chinese clinical practice standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis enrolled 90 patients receiving guselkumab and assessed efficacy from multiple dimensions, along with adverse events, drug survival, and metabolic indicators. Composite indices were used to evaluate coronary artery disease (CAD) and insulin resistance risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Guselkumab showed sustained efficacy over 76 weeks in Chinese patients. Body area analysis showed significantly faster clearance of head lesions, with 40.0% of patients achieving complete clearance at week 4, compared to only 16.0% for lower extremities (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). Baseline disease severity and switching to guselkumab due to inadequate response to prior biologics did not significantly affect treatment outcomes (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.05). Predictors of PASI 100 at week 52 included normal BMI (OR = 6.10, 95% CI: 1.54\u201323.96), no phototherapy history (OR = 0.17, 95% CI: 0.04\u20130.71), and biologic-na\u00efve status (OR = 0.14, 95% CI: 0.03\u20130.62). Mean fasting blood glucose (FBG) increased from 5.51 (0.74) to 5.65 (0.75) mmol\/L at week 52 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02). The Within Normal Limits (WNL) subgroup showed transient elevations in total cholesterol (week 28,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.049) and triglycerides (week 28,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009). Although these indicators increased, they remained within the normal range. The Abnormal Without Treatment (AWT) subgroup exhibited decreased uric acid (UA) at week 52 (471.00 \u00b1 51.06 to 418.72 \u00b1 64.35 \u03bcmol\/L;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004). Composite indices indicated no increased CAD or insulin resistance risk. Injection site reactions (32.2%) were the most common adverse events. Drug survival was 78.9% at 76 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms the durable efficacy and safety of guselkumab in Chinese patients with plaque psoriasis, with early response heterogeneity favoring the head. Treatment did not increase CAD or insulin resistance risk. Normal BMI and biologic-na\u00efve status were associated with superior efficacy, supporting precision management strategies that integrate cutaneous and systemic monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1684996","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:51:17Z","timestamp":1769532677000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards"],"prefix":"10.3389","volume":"17","author":[{"given":"Runlu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169063","article-title":"Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways","volume":"23","author":"Piaserico","year":"2022","journal-title":"IJMS"},{"key":"B4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-022-02617-5","article-title":"Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0505-z","article-title":"IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis","volume":"9","author":"Hou","year":"2018","journal-title":"Protein Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1964420","article-title":"A non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"mAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"Acad Dermatol Venereol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17710","article-title":"Real-world safety and effectiveness of guselkumab in patients with psoriasis: A post-marketing surveillance study through up to week 52 in Japan","volume":"52","author":"Tada","year":"2025","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17400","article-title":"Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas","volume":"63","author":"Rompoti","year":"2024","journal-title":"Int J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jdv.19403","article-title":"Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study","volume":"39","author":"Puig","year":"2025","journal-title":"Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.645550","article-title":"Updated evidence of the association between elevated serum uric acid level and psoriasis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112704","article-title":"Role of glucose metabolism reprogramming in keratinocytes in the link between psoriasis and metabolic syndrome","volume":"139","author":"Yan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126561","article-title":"Aberrations in lipid expression and metabolism in psoriasis","volume":"22","author":"Nowowiejska","year":"2021","journal-title":"IJMS"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S293107","article-title":"Comorbid psoriasis and metabolic syndrome: clinical implications and optimal management","volume":"12","author":"De Brandt","year":"2022","journal-title":"PTT"},{"key":"B20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"Acad Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12933-024-02163-9","article-title":"Associations of the triglyceride-glucose index and atherogenic index of plasma with the severity of new-onset coronary artery disease in different glucose metabolic states","volume":"23","author":"Wu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","article-title":"Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations","volume":"21","author":"Tao","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01327-5","article-title":"Biologic therapy and cardiometabolic risk in psoriasis: A retrospective review","volume":"15","author":"Smith","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03042-1","article-title":"Comparison of on-label treatment persistence in real-world patients with psoriatic arthritis receiving guselkumab versus subcutaneous interleukin-17A inhibitors","volume":"42","author":"Mease","year":"2025","journal-title":"Adv Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017743268","article-title":"Treating moderate-to-severe plaque psoriasis with guselkumab: A review of phase II and phase III trials","volume":"52","author":"Howell","year":"2018","journal-title":"Ann Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1959504","article-title":"Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study","volume":"33","author":"Blauvelt","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.05.005","article-title":"Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison","volume":"100","author":"Sel\u00e7uk","year":"2025","journal-title":"Anais Brasileiros Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16008","article-title":"Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"178","author":"Gordon","year":"2018","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092552","article-title":"Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 3-year multicenter study","volume":"13","author":"Megna","year":"2024","journal-title":"JCM"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"Acad Dermatol Venereol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1141086","article-title":"Microdialysis as a tool for antibiotic assessment in patients with diabetic foot: a review","volume":"14","author":"Fejfarov\u00e1","year":"2023","journal-title":"Front Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13816","article-title":"IL -17-positive mast cell infiltration in the lesional skin of lichen planopilaris: Possible role of mast cells in inducing inflammation and dermal fibrosis in cicatricial alopecia","volume":"29","author":"Hobo","year":"2020","journal-title":"Exp Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18733","article-title":"High capillary diameter in psoriatic plaques of the lower legs","volume":"182","author":"Lacarrubba","year":"2020","journal-title":"Br J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14944","article-title":"Investigation of prevalence of biologic use and discontinuation rates in moderate-to-severe psoriasis patients in Newfoundland and Labrador using real-world data","volume":"34","author":"Gulliver","year":"2021","journal-title":"Dermatol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad446","article-title":"BADBIR Study Group. Characteristics of \u201csuper responders\u201d and \u201csuper nonresponders\u201d to first biologic monotherapy for psoriasis: a nested case-control study","volume":"190","author":"Mason","year":"2024","journal-title":"Br J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18314","article-title":"Risankizumab shows faster response in bio na\u00efve than in bio-experienced psoriatic patients","volume":"36","author":"Mastorino","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","article-title":"Switching biologics in psoriasis - practical guidance and evidence to support","volume":"13","author":"Tsai","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2023.4555","article-title":"Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics","volume":"33","author":"Kim","year":"2023","journal-title":"Eur J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"Acad Dermatol Venereol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12793","article-title":"When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab","volume":"32","author":"Damiani","year":"2019","journal-title":"Dermatol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"Acad Dermatol Venereol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00403-024-03403-4","article-title":"Residual metabolic burden in young psoriasis patients successfully treated with biologics","volume":"316","author":"Merzel \u0160abovi\u0107","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2260304","article-title":"Does biological agent treatment have an impact on serum uric acid levels in patients with psoriasis","volume":"39","author":"Tamer","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002130","article-title":"Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin Med J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","article-title":"Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study","volume":"15","author":"Ntawuyamara","year":"2025","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2025.2570206","article-title":"Effect of interleukin 23 inhibitors (risankizumab and guselkumab) on cardiovascular and cerebrovascular risk in psoriasis patients","volume":"44","author":"Y\u0131ld\u0131z","year":"2025","journal-title":"Cutan Ocul Toxicol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20220839","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2023 edition)","volume":"56","year":"2023","journal-title":"Chin J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1684996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:51:18Z","timestamp":1769532678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1684996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1684996"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1684996","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1684996"}}